Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide binds to glucocorticoid receptors inside ocular cells, altering gene transcription. This reduces the production of inflammatory cytokines, limits leukocyte infiltration, and decreases vascular permeability, resulting in long‑lasting control of intra‑ocular inflammation and edema.

The dose of Iluvien is determined by the prescribing ophthalmologist. The product is supplied as a single 0.19 mg intravitreal implant that is surgically placed in the vitreous cavity, and the clinician decides whether one or more implants are required based on the patient’s condition.

The safety of Iluvien in pregnancy and lactation has not been established. Because systemic exposure is possible, it should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Iluvien offers a sustained‑release corticosteroid implant that can provide up to three years of therapy from a single injection, reducing the need for frequent intravitreal injections. Alternative options include anti‑VEGF agents, which require monthly or bimonthly dosing, and other corticosteroid implants with different release profiles.

Iluvien should be stored at controlled room temperature, kept in its original packaging, and protected from light and moisture. The implant must be handled in a sterile environment by qualified ophthalmic surgeons during the intravitreal insertion procedure.

Iluvien is administered by a trained ophthalmic surgeon who inserts the 0.19 mg intravitreal sustained‑release implant into the vitreous cavity through a minimally invasive procedure. No additional dosing is required until the implant’s effect diminishes, at which point re‑implantation may be considered.

Serious risks include elevated intraocular pressure that may lead to glaucoma, cataract formation, endophthalmitis (eye infection), retinal detachment, and rare cases of implant migration. Patients should be monitored regularly for these complications, and any signs of infection or vision loss require immediate medical attention.

Iluvien is contraindicated in patients with active ocular infection, known hypersensitivity to fluocinolone acetonide or any component of the implant, and those with uncontrolled glaucoma where further intraocular pressure rise would be hazardous. The decision to treat should be individualized by the ophthalmologist.